SCHEMBL188105

SCHEMBL188105

CC[C@H](C)C(=O)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3860250 1.00
SCHEMBL8768172 1.00 FFAR3 (0.35)
SCHEMBL43232 1.00
SCHEMBL29396747 1.00 FFAR3 (0.35)
SCHEMBL11607991 0.97 FOLH1 (0.33)
SCHEMBL28015494 0.97 FOLH1 (0.33)
L-Lactic Acid SCHEMBL31285806 0.90 TP53 (0.52)
SCHEMBL108300 0.84 TSHR (0.41)
2-Oxoisohexanoate SCHEMBL25436317 0.84 CA2 (0.38)
SCHEMBL3755021 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119899102-A Synthesis method of alpha-ketoisoleucine calcium intermediate and application of alpha-ketoisoleucine calcium intermediate in preparation of alpha-ketoisoleucine calcium 河北天成药业股份有限公司 2025-04-29 CN claimed
WO-2024150158-A1 IL-7 POLYPEPTIDES, IMMUNOCYTOKINES COMPRISING SAME, AND USES THEREOF BRIGHT PEAK THERAPEUTICS AG (CH) 2024-07-18 WO claimed
EP-4366780-A1 SYNTHETIC IL-7 AND IL-7 IMMUNOCYTOKINES Bright Peak Therapeutics AG (CH) 2024-05-15 EP claimed
US-20230405091-A1 METHODS OF MODULATING GASTROINTESTINAL METABOLITES DSM IP ASSETS B.V. (NL) 2023-12-21 US claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
EP-4228424-A1 METHODS OF MODULATING GASTROINTESTINAL METABOLITES DSM IP Assets B.V. (NL) 2023-08-23 EP claimed
CN-116390651-A Methods of modulating gastrointestinal metabolites 帝斯曼知识产权资产管理有限公司 2023-07-04 CN claimed
US-20230200412-A1 METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES DSM IP ASSETS B.V. (NL) 2023-06-29 US claimed
EP-4200323-A2 MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF Bright Peak Therapeutics AG (CH) 2023-06-28 EP claimed
EP-4118090-A1 METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES DSM IP Assets B.V. (NL) 2023-01-18 EP claimed
WO-2021183896-A1 METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES DSM IP ASSETS, B.V. (NL) 2021-09-16 WO claimed
US-20180003721-A1 Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients JOSLIN DIABETES CENTER (US) 2018-01-04 US claimed
WO-2016115496-A1 METABOLITE BIOMARKERS PREDICTIVE OF RENAL DISEASE IN DIABETIC PATIENTS JOSLIN DIABETES CENTER (US) 2016-07-21 WO claimed
US-8494779-B2 Method for screening essential metabolites in growth of microorganisms KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-07-23 US claimed
US-20100143911-A1 METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-06-10 US claimed
EP-2097743-A1 METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS Korea Advanced Institute of Science and Technology (KR) 2009-09-09 EP claimed
WO-2008078911-A1 METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2008-07-03 WO claimed
EP-0921186-B1 Use of ethyl 3-methyl-2-oxopentanoate as a perfuming ingredient FIRMENICH & CIE (CH) 2004-11-03 EP claimed
EP-0921186-A2 Use of ethyl 3-methyl-2-oxopentanoate as a perfuming ingredient FIRMENICH SA (CH) 1999-06-09 EP claimed
EP-0406811-A2 Novel clathrate compounds and a drug comprising them AJINOMOTO CO., INC. (JP) 1991-01-09 EP claimed